Cretostimogene Grenadenorepvec (CG0070): An Oncolytic Immunotherapy for Bladder Cancer

I. Introduction to CG0070 (Cretostimogene Grenadenorepvec)

A. Overview and Investigational Status

Cretostimogene grenadenorepvec, also widely known by its investigational identifier CG0070, is an advanced oncolytic immunotherapy currently undergoing late-stage clinical development. Its primary therapeutic focus is the treatment of bladder cancer, with a significant emphasis on Non-Muscle Invasive Bladder Cancer (NMIBC).[1] The agent is being developed by CG Oncology, a biopharmaceutical company dedicated to urologic oncology.[4] CG0070 is formulated as a solid preparation intended for intravesical administration directly into the bladder.[6] This local delivery mechanism is a key feature of its therapeutic strategy.

The concurrent use of the alphanumeric identifier "CG0070" and the more formal proposed non-proprietary name "Cretostimogene Grenadenorepvec" in recent scientific literature and company communications [1] reflects the agent's progression through the clinical development pipeline. Typically, investigational compounds are initially designated by such codes. As a drug advances to late-stage trials and approaches potential regulatory submission, a non-proprietary (generic) name is adopted. This transition facilitates standardized communication among healthcare professionals, regulatory bodies, and the broader scientific community, and is a recognized marker of developmental maturity towards potential commercialization.

B. Drug Identification

For standardized referencing, Cretostimogene Grenadenorepvec is cataloged in the DrugBank database under the accession number DB05148.[6]

C. Clarification of Drug Classification: Oncolytic Virus (Biologic)